Alivus Life Sciences schedules investor meetings with Mirae Asset, Emkay

Alivus Life Sciences Limited has scheduled a series of one-on-one meetings with investors and analysts from August 28 to September 2, 2026. The engagements include discussions with Mirae Asset (US), Emkay Global, SIMPL, and Lyptus Capital.

The company disclosed the schedule under Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. The meetings will be conducted via both virtual and in-person modes.

Meeting Schedule

Date	Participant	Mode	Location	Type
August 28, 2026	Mirae Asset (US)	Virtual	-	One on One
September 1, 2026	Emkay Global	In-person	Mumbai	One on One
September 1, 2026	SIMPL	In-person	Mumbai	One on One
September 2, 2026	Lyptus Capital	Virtual	-	One on One

The company noted that the schedule and mode of the meetings may change due to exigencies on the part of the investor, analyst, or the company.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.30%	-3.30%	+22.45%	+52.60%	+39.01%	+101.74%

Alivus Life Sciences Limited has announced the acquisition of a 76% stake in IQGenX Pharma Private Limited for ₹9.12 crore. The transaction marks a strategic expansion into formulation development, leveraging the target’s expertise in oral solids, sterile injectables, and ophthalmic solutions for regulated markets including the US, EU, and Latin America.

Acquisition details

The key parameters of the board-approved transaction are outlined below:

Parameter:	Details
Target company:	IQGenX Pharma Private Limited
Stake acquired:	76% (8,60,589 equity shares)
Transaction value:	₹9.12 crore
Approving body:	Board of Directors
Expected closure:	December 6, 2026

The acquisition enables Alivus to extend its operational footprint beyond its core Active Pharmaceutical Ingredients (APIs) business. By integrating IQGenX’s platform, Alivus aims to create an end-to-end service model that includes pre-formulation studies, prototype development, process optimisation, and regulatory submission support.

Strategic rationale

While APIs anchor Alivus’s existing operations, this move allows the company to leverage its portfolio selectively into advanced formulation development. The combined entity will offer deep scientific expertise across complex delivery formats, supported by rigorous bioequivalence and stability studies.

Key strategic objectives include:

Expanding the global customer base in the generic pharmaceutical segment.
Scaling value propositions for Contract Development and Manufacturing Organisation (CDMO) customers through seamless scale-up and clinical supplies.
Curating a high-impact basket of differentiated, niche assets, primarily in Oncology, for strategic out-licensing.

IQGenX Pharma, founded in October 2016, operates as a custom research organization specializing in formulation development for highly regulated markets. Alivus plans to utilise IQGenX’s specialised platform alongside its own world-class API portfolio to enhance its competitive positioning.

Financial profile of target

IQGenX Pharma Private Limited is registered at Navi Mumbai, Maharashtra. The company reported a turnover of ₹348.0 lakh for the financial year ended March 31, 2026 (FY26). This represents growth from ₹318.2 lakh in FY25 and ₹267.5 lakh in FY24.

Closing timeline

The acquisition is subject to customary closing condition precedents. The company expects the transaction to close by December 6, 2026, or such date as may be agreed upon from the execution of the Share Purchase Agreement (SPA).

The SPA stipulates that if the conditions precedent are not met within the specified timeline, the sellers will enter into a Business Transfer Agreement with Alivus, whereby the entire business, including employees and assets, will be acquired by the company.